Table 5.

Association of CaSR Expression With Lethal Prostate Cancer Stratified by VDR Expression and PTEN Tumor Status Among Men Diagnosed With Prostate Cancer Between 1983 and 2009 in the HPFS and the PHS

	Na	Lethalb	Person-Years	Model 1c	Pinteraction Valued	Model 2e	Pinteraction Valued
CaSR/VDR expression
Low CaSR/high VDRf	214	12	3114	Reference	.16	Reference	.07
Low CaSR/low VDRf	429	32	6260	1.3 (0.7–2.6)		1.0 (0.5–2.0)
High CaSR/high VDR	37	3	641	1.2 (0.3–4.3)		0.8 (0.2–3.0)
High CaSR/low VDR	49	12	711	4.5 (2.0–10.0)		3.2 (1.4–7.3)
CaSR/PTEN status
Low CaSR/PTEN intact	649	29	8788	Reference	.13	Reference	.56
Low CaSR/PTEN loss	227	21	3030	2.1 (1.2–3.7)		1.4 (0.8–2.4)
High CaSR/PTEN intact	76	5	1080	1.4 (0.5–3.6)		1.6 (0.6–4.1)
High CaSR/PTEN loss	25	8	333	7.8 (3.6–17.1)		3.1 (1.4–7.1)

^aNumber of total observations.

^bNumber of lethal events.

^cAdjusted for age at diagnosis.

^dP value of VDR and CaSR or PTEN and CaSR multiplicative interaction is based on the Wald test.

^eAdjusted for age at diagnosis, BMI at diagnosis, Gleason grade, and pathological TNM.

^fHigh VDR is the upper one-third of expression; low VDR is the lower two-thirds of expression.